Trial Profile

An Open-Label Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Povorcitinib (Primary) ; Digoxin; Metformin; Rosuvastatin
Indications Asthma; Chronic urticaria; Hidradenitis suppurativa; Prurigo nodularis; Skin disorders; Vitiligo
Focus Pharmacokinetics
Sponsors Incyte Corporation

06 Feb 2025 Status changed from recruiting to completed.
12 Dec 2024 Planned End Date changed from 23 Nov 2024 to 11 Jan 2025.
12 Dec 2024 Planned primary completion date changed from 23 Nov 2024 to 11 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com